<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="400">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01132664</url>
  </required_header>
  <id_info>
    <org_study_id>CBKM120X2107</org_study_id>
    <secondary_id>2009-015417-46</secondary_id>
    <nct_id>NCT01132664</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab</brief_title>
  <official_title>A Phase Ib/II, Open Label, Multi-center Study Evaluating the Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Spain: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of BKM120 in combination with trastuzumab in
      patients with relapsing HER2 overexpressing breast cancer who have previously failed
      trastuzumab.

      The study will further assess the safety and preliminary efficacy of BKM120 in combination
      with trastuzumab and capecitabine in patients with relapsing HER2 overexpressing breast
      cancer and brain metastases who have previously failed trastuzumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse event frequencies by patient and DLT frequencies by cohort</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an objective response after at least two cycles of therapy</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Trastuzumab</condition>
  <condition>BKM120</condition>
  <condition>HER2+</condition>
  <arm_group>
    <arm_group_label>HER2+ metastatic breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2+ metastatic breast cancer with BM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <arm_group_label>HER2+ metastatic breast cancer</arm_group_label>
    <arm_group_label>HER2+ metastatic breast cancer with BM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  World Health Organization (WHO) Performance Status of ≤ 2

          -  Patients with HER2+ breast cancer by local laboratory testing (immunohistochemistry
             [IHC] 3+ staining or fluorescence in situ hybridization [FISH] confirmation for IHC
             2+ and 1+)

          -  Documented tumor resistance to trastuzumab:

               -  Recurrence while on trastuzumab or within 12 months since the last infusion for
                  patients who received trastuzumab as adjuvant treatment

               -  Progression while on or within 4 weeks since the last infusion of trastuzumab
                  for patients who received trastuzumab for metastatic disease.

          -  Documented evidence of progressive disease per Response Evaluation Criteria in Solid
             Tumors (RECIST) on trastuzumab-based therapy defined as:

               -  Phase Ib: at any time before study entry

               -  Phase II: within 16 weeks before date of first dosing

          -  Received at least 1 but no more than 4 prior anit-HER2 based regimens including at
             least 1 regimen containing trastuzumab (adjuvant or neo-adjuvant trastuzumab will be
             considered as one prior regimen).  HER2 directed therapies are defined as comprising
             trastuzumab, lapatinib, and trastuzumab-DM1 (T-DM1) only.

             • Phase II only: trastuzumab, T-DM1 or lapatinib must be part of the most recent line
             of therapy

          -  Previous lines of cytotoxic chemotherapy:

               -  Phase Ib: no more than 4 lines of cytotoxic chemotherapy

               -  Phase II: no more than 3 lines of cytotoxic chemotherapy

        Measurable disease:

          -  Phase Ib: patient has at least one measurable lesion or non-measurable disease as
             defined per RECIST

          -  Phase II: patient has at least one measureable lesion as defined per RECIST

        // Specific Inclusion Criteria for patients in BM cohorts:

          -  Patient has evidence of progressing brain metastases and/or new metastatic brain
             lesion(s) without leptomeningeal disease.

          -  Patient has received prior WBRT and/or SRS at at &gt;28 and &gt;/= 14 days, respectively,
             prior to starting study drug and the patient must have recovered from the side
             effects of the therapy

          -  WHO performance status of &lt;/=1

          -  PT INR &lt;/= 1.5

          -  Any number of prior HER2-directed and cytotoxic regimens, and the most recent line
             may be any type of anti-neoplastic therapy

        // Exclusion Criteria:

          -  Patients with untreated brain metastases

          -  Patients with acute or chronic liver, renal disease or pancreatitis

          -  Patients with any peripheral neuropathy ≥ Common Terminology Criteria for Adverse
             Events (CTCAE) grade 2

          -  Patients with a history of mood disorders or ≥ CTCAE grade 3 anxiety

          -  Patient with clinical manifest diabetes mellitus or steroid-induced diabetes mellitus

        // Specific Exclusion Criteria for patients in BM cohorts

          -  Prior treatment with capecitabine

          -  Patient has known dihydropyrimidine dehydrogenase (DPD) deficiency

          -  Patient is currently receiving treatment with EIAED

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone_ext>+41613241111</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham/ Kirklin Clinic Univ AL - PI</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shameka Clark</last_name>
      <phone>205-934-0337</phone>
      <email>mekac@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Andres Forero-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers SC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group Dept of Highlands Oncology Grp</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Weaver</last_name>
      <phone>+1 479 872 8130</phone>
      <email>vweaver@hogonc.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Thaddeus Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles UCLA LeConte Location</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Cancer Center Memorial Breast</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Palm Beach Cancer Institute PB Cancer</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center Study Coordinator</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital Ingalls Mem Hosp</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Lueder</last_name>
      <phone>708-915-6119</phone>
      <email>plueder@ingalls.org</email>
    </contact>
    <investigator>
      <last_name>Mark Kozloff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Center</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (6)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Green</last_name>
      <phone>313-576-9373</phone>
      <email>greenb@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Patricia M. LoRusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine-Siteman Cancer Ctr WA Siteman</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Rensink</last_name>
      <phone>314-747-8085</phone>
      <email>brensink@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Pluard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center BIMC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahir Mirziyev</last_name>
      <phone>212-844-8292</phone>
      <email>tmirzoye@chpnet.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Malamud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Duke South 2</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delinda Phillips</last_name>
      <phone>+1 919 660 1278</phone>
      <email>delinda.phillips@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Kelly Marcom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic Dept. of the West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Sarah Cannon Cancer Center SC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiktoria Raby</last_name>
      <email>wiktoria.raby@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Johanna Chock Bendell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center CTRC at the UTHSCSA (2)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research SCCA - Freh Hutch</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Univ Wisc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Herblain Cédex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Macerata</city>
        <state>MC</state>
        <zip>62100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Terni</city>
        <state>TN</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 19, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <keyword>BKM120</keyword>
  <keyword>PIK3</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>brain metastases</keyword>
  <keyword>Herceptin</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>open-label</keyword>
  <keyword>maximum tolerated dose</keyword>
  <keyword>Phase I</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
